Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06172660 · ClinicalTrials.gov registry record
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
A clinical trial of RSV Infection, sponsored by Yale University.
- Recruiting
- Registry status
- 3,750
- Enrollment target
- 1
- Study location
NCT06172660: Recruiting study of RSV Infection, sponsored by Yale University.
NCT06172660 is a study of RSV Infection that is actively recruiting participants, run by Yale University. The registered enrollment target is 3,750 participants, above the 278-participant average among 8 other RSV Infection trials with a reported enrollment target (1249% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06172660, a study of RSV Infection, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- 3,750 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to continue evaluating how well the RSV vaccines work as they are currently being used in routine clinical practice. Some of the questions that the investigators hope to answer with this study are: 1) What is the overall effectiveness of these vaccines? 2) How long does immunity last? 3) How effective are the vaccines against new strains? 3) Does the vaccine's effectiveness vary by age?
Primary Outcome
The overall effectiveness of each immunoprophylactic strategy (monoclonal antibodies and maternal immunization) will be estimated separately. Logistic regression models will be used for analysis, with the outcome being case/control status and immunization status as the main predictor, controlling for known confounders.
Conditions Studied
Interventions
- DRUG Nirsevimab
Study Locations (1)
Connecticut
- Yale Child Health Research Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,750 participants |
| Start Date | 2024-10-28 |
| Est. Completion | 2028-12-30 |
What NCT06172660 shows while recruiting
NCT06172660 is an observational study that tracks outcomes without assigning an intervention. Its 3,750 participants enrollment target places it among the larger protocols in the corpus, above the 278-participant average among 8 other RSV Infection trials with a reported enrollment target (1249% higher).
The record links to 1 condition, with RSV Infection appearing as the primary indexed condition, and to 1 intervention - of which Nirsevimab is the first listed.
NCT06172660 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06172660 about?
NCT06172660 is a clinical study titled "Real-World Effectiveness of Perinatal RSV Immunoprophylaxis". The purpose of this study is to continue evaluating how well the RSV vaccines work as they are currently being used in routine clinical practice. Some of the questions that the investigators hope to answer with this study are: 1) What is the overall effectiveness of these vaccines? 2) How long does ...
What is the current status of trial NCT06172660?
This trial is currently recruiting. The enrollment target is 3,750 participants. The study started on 2024-10-28. Estimated completion is 2028-12-30.
What conditions does trial NCT06172660 study?
This clinical trial studies the following conditions: RSV Infection.
What interventions are being tested in trial NCT06172660?
The interventions under investigation include: Nirsevimab (DRUG).
Who is sponsoring clinical trial NCT06172660?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06172660 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for RSV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06172660's enrollment target sits among peer trials
3,750 1st of 8 higher than 8 of 8 other RSV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other RSV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
RECRUITING · Phase 1
-
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
RECRUITING · Phase 3
-
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies
ACTIVE NOT RECRUITING
-
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
COMPLETED · Phase 3
-
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
COMPLETED · Phase 1
-
A Study of EDP-323 in Healthy Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06298253 · 3,750 participants · NA
Behavioral Economics to Implement a Traffic Light Nutrition Ranking System: Study 2
- NCT06076304 · 3,720 participants · Phase 4
Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis
- NCT04573660 · 3,784 participants
Abbott Vascular Medical Device Registry
- NCT06401863 · 3,691 participants · NA
Shared Decision for Drug Interactions in Oral Anticoagulation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI